All posts of jessi

Strong and profitable growth continued in 2017

19.4.2018 Contract research organization StatFinn – EPID Research reports record growth in 2017. The financial statement shows total sales of € 7,2 million (2016: 4,7 million) with a growth rate of 53,7 percent (49,2). Earnings before taxes grew to € 1,1 million (0,7). “I am extremely pleased with our achievements in 2017. During the year, we […]

We presented three posters at ICPE Montreal

30.08.2017 – We presented three posters at ICPE Montreal, the 33rd International Conference on Pharmacoepidemiology & Therapeutic Risk Management. The conference was held in Montreal August 26 – August 30, 2017. We presented the following posters: Spotlight poster: Adjusting for unobserved disease severity using individuals as their own controls – An example from a schizophrenia study Pioglitazone […]

Attendance at ICPE 2017 in Montreal, Canada

26.6.2017 – We are proud to sponsor 33rd ICPE, International Conference on Pharmacoepidemiology & Therapeutic Risk Management, that will be held in Montreal, Canada this year. We look forward to meeting you! We will have an exhibition booth there for you to find us easily and to give you more information about the pharmacoepidemiological Real-World […]

New article on pharmacological treatments and risk of readmission to hospital for unipolar depression

01.06.2017 – Our new article on pharmacological treatments and risk of readmission to hospital for unipolar depression has been published in The Lancet. Little is known about the comparative effectiveness of long-term pharmacological treatments for severe unipolar depression. We aimed to study the effectiveness of pharmacological treatments in relapse prevention in a nationwide cohort of […]

New article on pioglitazone use and risk of mortality in patients with type 2 diabetes

30.5.2017 – Our new article on pioglitazone use and risk of mortality in patients with type 2 diabetes has been published in BMJ Open. Life expectancy is 5–10 years shorter in adult patients with newly-diagnosed diabetes than in the general population. Cardiovascular diseases are the leading cause of death in this patient group. Pioglitazone, which is an oral […]

New article on oral anticoagulation therapy among patients with atrial fibrillation

27.4.2017 – Our new article on oral anticoagulation therapy among patients with atrial fibrillation has been published in Pharmacoepidemiology and Drug Safety. Use of oral anticoagulation therapy remarkable decreases the risk of stroke and other thromboembolic events in patients with atrial fibrillation (AF). Despite of newer anticoagulants on the market, warfarin still is the most commonly used […]

StatFinn and EPID Research present strong growth in 2016

11.04.2017 – StatFinn and EPID Research achieved strong and profitable growth in 2016. Following the 2-digit growth from the previous financial year, the results show that the merged company continues the global expansion with solid basis, resources and talent. Read more details in the official press release. Press release EN – Press release FI

New article on insulins and risk of severe hypoglycemia

17.2.2017 – Our new article on insulins NPH, glargine, and detemir, and risk of severe hypoglycemia has been published in Annals of Medicine. The comparative safety of modern basal insulins regarding hypoglycemia among the working-age population has been unclear. Large reductions in the incidence of severe hypoglycemia were seen among real-life patients who started insulin detemir, as […]
  • 1
  • 2